Notably, BCL-xL inhibition both alone (healthy: 81.72 ± 6.86%; BP-CML: 52.07 ± 10.58%) and with BCL-2 inhibition (healthy: 47.14 ± 7.61%; BP-CML: 18.63 ± 7.51%) significantly reduced the cell counts of BP-CML samples to a greater extent than those of the healthy controls (p = 0.0086, p = 0.0121 respectively), indicating a potential therapeutic window. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.